GlassScriptPhysician profile
Jody L Root
NPI 1881622900
$2,766.37
in general payments reported to CMS, 2019-2025
13 companies · $850 in 2025
The $850 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $362 · 2022: $627 · 2023: $621 · 2024: $307 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.47 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $821.54 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $650.93 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $398.94 | 2025 | Austedo Xr, Uzedy |
| Novo Nordisk INC | $255.03 | 2022-2025 | Rybelsus, Ozempic |
| Alkermes, INC. | $186.42 | 2025 | Lybalvi, Aristada |
| Otsuka America Pharmaceutical, INC. | $140.35 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $108.49 | 2021-2024 | Mounjaro, Zepbound |
| Vanda Pharmaceuticals INC. | $83.06 | 2025 | Fanapt |
| Exact Sciences Corporation | $31.89 | 2023 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $26.77 | 2023 | Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $26.42 | 2021-2022 | |
| Eisai INC. | $19.26 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.27 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jody Root listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.